|Articles|August 21, 2007

GlaxoSmithKline Receives New HHS Order

Author(s)BioPharm International Editors

GlaxoSmithKline (London, UK, www.gsk.com) has received another order from the US Department of Health and Human Services (HHS) for 22.5 million doses of bulk H5N1 antigen for the US national stockpile of pre-pandemic vaccines.

GlaxoSmithKline (London, UK, www.gsk.com) has received another order from the US Department of Health and Human Services (HHS) for 22.5 million doses of bulk H5N1 antigen for the US national stockpile of pre-pandemic vaccines. This is in addition to the 5 million doses of H5N1 bulk antigen ordered by the HHS in November 2006.

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!